Chronic Heart Failure Treating Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 Table 69: Summary of studies included in the review Study Intervention and comparison Population Outcomes Comments HEART CABG plus medical therapy n = 30 PCI plus medical therapy n = 15 Medical therapy n = 64 Age, median (IQR): therapy 69 (60 74). %Male: CABG/PCI 94; medical therapy 93. NYHA class, n: I CABG/PCI - 13; medical therapy - II CABG/PCI 28; medical therapy - III/IV CABG/PCI 28; medical therapy 22. All-cause mortality; Dichotomous Quality of life difference between the groups reported only. Quality of life - Minnesota Living With Heart Failure Questionnaire; Mean difference between the groups reported only. Median follow-up of 4.9 years. Only 138 of the planned 800 patients were enrolled because of withdrawal of funding due to slow recruitment and because the larger STICH trial became available. CABG plus medical therapy n = 610 Medical therapy n = 602 Age year, median (IQR): medical therapy 59 (53-67). %Male: CABG 88; medical therapy 88. NYHA class, n: I CABG 65, medical therapy II IV CABG 545; medical therapy 528. All-cause mortality at 30 days and 5 years Quality of life Kansas City Cardiomyopathy Questionnaire. Adjusted mean difference Quality of life state index); Adjusted mean difference Quality of life Adjusted mean difference Quality of life Adjusted mean difference All-cause hospitalisations Median follow-up of 9.8 years. The use of implantable defibrillators was encouraged as part of standard medical therapy. Data was adjusted for patients for repeated assessments of quality of life. Chronic Heart Failure Treating Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 Study Intervention and comparison Population Outcomes Comments Stroke Subsequent procedures CABG Subsequent procedures PCI No. 